Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Cash Flow Conversion Efficiency
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A cash flow conversion efficiency. Based on the latest financial reports, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥15.57 Million ≈ $2.28 Million USD) by net assets (CN¥5.73 Billion ≈ $838.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
Cash flow conversion efficiency of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025. This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Wuhan Easy Diagnosis Biomedicine Co Ltd share price for real-time trading data and today's change.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Cash Flow Conversion Ratio Explained
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A ranked by their cash flow conversion efficiency. Also see 002932 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huali Industries
SHG:603038
|
-0.005x |
|
Weyco Group Inc
NASDAQ:WEYS
|
0.030x |
|
Gansu Golden Glass Technologies Co Ltd
SHE:300093
|
0.043x |
|
Zhejiang Tiancheng Control Co
SHG:603085
|
0.100x |
|
Ponce Financial Group Inc
NASDAQ:PDLB
|
0.014x |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
0.066x |
|
Masoval AS
OL:MAS
|
0.159x |
|
Gemtek Technology Co Ltd
TW:4906
|
0.095x |
Annual Cash Flow Conversion Efficiency for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below shows the annual cash flow conversion efficiency of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025. Review 002932 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.66 Billion ≈ $827.62 Million |
CN¥-70.05 Million ≈ $-10.25 Million |
-0.012x | +12.34% |
| 2024-12-31 | CN¥6.02 Billion ≈ $880.72 Million |
CN¥-85.05 Million ≈ $-12.44 Million |
-0.014x | -122.65% |
| 2023-12-31 | CN¥6.29 Billion ≈ $920.73 Million |
CN¥392.50 Million ≈ $57.43 Million |
0.062x | -89.47% |
| 2022-12-31 | CN¥6.77 Billion ≈ $990.93 Million |
CN¥4.01 Billion ≈ $587.21 Million |
0.593x | +49.86% |
| 2021-12-31 | CN¥2.85 Billion ≈ $417.06 Million |
CN¥1.13 Billion ≈ $164.92 Million |
0.395x | +22.57% |
| 2020-12-31 | CN¥1.11 Billion ≈ $163.14 Million |
CN¥359.68 Million ≈ $52.63 Million |
0.323x | +783.28% |
| 2019-12-31 | CN¥615.62 Million ≈ $90.08 Million |
CN¥22.49 Million ≈ $3.29 Million |
0.037x | -59.67% |
| 2018-12-31 | CN¥592.59 Million ≈ $86.72 Million |
CN¥53.67 Million ≈ $7.85 Million |
0.091x | -52.68% |
| 2017-12-31 | CN¥242.93 Million ≈ $35.55 Million |
CN¥46.50 Million ≈ $6.80 Million |
0.191x | -43.07% |
| 2016-12-31 | CN¥175.08 Million ≈ $25.62 Million |
CN¥58.86 Million ≈ $8.61 Million |
0.336x | -13.84% |
| 2015-12-31 | CN¥115.39 Million ≈ $16.89 Million |
CN¥45.02 Million ≈ $6.59 Million |
0.390x | +17.45% |
| 2014-12-31 | CN¥49.59 Million ≈ $7.26 Million |
CN¥16.47 Million ≈ $2.41 Million |
0.332x | -28.26% |
| 2013-12-31 | CN¥13.60 Million ≈ $1.99 Million |
CN¥6.30 Million ≈ $921.32K |
0.463x | -36.17% |
| 2012-12-31 | CN¥1.42 Million ≈ $208.28K |
CN¥1.03 Million ≈ $151.10K |
0.725x | +103.22% |
| 2011-12-31 | CN¥21.45K ≈ $3.14K |
CN¥-482.90K ≈ $-70.66K |
-22.514x | -- |
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more